Category: pSivida Corp.
The UK's National Institute for Health & Care Excellence OK's pSivida's Iluvien drug/device combo for cataract surgery patients with chronic diabetic macular edema.
pSivida (NSDQ:PSDV) said the UK's National Institute for Health & Care Excellence approved its Iluvien drug/device combination.
The approval is for cataract surgery patients who don't respond to standard treatment for diabetic macular edema, according to a press release.
Wall Street flees from pSivida and licensee Alimera Sciences as the FDA hands down its 3rd rejection for the Iluvien vision repair implant.
France grants Alimera's Iluvien vision repair implant national insurance coverage, with up to 100% reimbursement for certain patients.
The French National Health Authority granted Alimera Sciences (NSDQ:ALIM) national insurance coverage for the Iluvien vision repair implant, the company said this week.
Gamma Medica says it's closed an $18 million Series A funding round for its molecular breast imaging device.
Gamma Medica said it's closed a $16 million Series A round from Psilos Group Managers.
The Northridge, Calif.-based company said it plans to use the cash to expand the commercial footprint of its LumaGen molecular breast imaging device and the LumaGuide biopsy model.
pSivida kicks off enrollment in the 1st of 2 planned efficacy trials for a drug/device combo to treat eye inflammation and prevent vision loss.
pSivida (NSDQ:PSDV) started recruiting patients in a Phase III U.S. trial for its eyelash-sized drug/device combination, an implant designed to treat ocular swelling that can lead to blindness.
A blogger's speculation that pSivida might be in line for a buyout bid sends the ophthalmology company's shares up nearly 4% today to a 52-week high.
Shares of ophthalmology company pSivida (NSDQ:PSDV) hit a 52-week high today on speculation from a Seeking Alpha blogger that it's ripe for an acquisition this year.
PSDV shares hit $3.96 each today, a 52-week high, having gained some 15.5% since a blogger writing as "Bob's Stocks" published the rumor yesterday.
German healthcare regulators approve pSivida’s Iluvien drug-device combination product for treatment of diabetic macular edema.
pSivida's (NSDQ:PSDV) announced that it won German approval for its Iluvien drug-device combination, launching immediately and touting the 1st commercial treatment this month in Deutschland on a patient with diabetic macular edema.